Protara Therapeutics, Inc. (TARA)

In the past six months, Protara Therapeutics' stock has been influenced by equity-based compensation grants, its inclusion in the Russell 3000 Index, and the release of its Q2 and Q1 2025 earnings reports. Positive interim results from the Phase 2 ADVANCED-2 trial of TARA-002 for NMIBC were highlighted. Jones Trading initiated coverage with a "Buy" recommendation, and analysts have maintained a "Strong Buy" consensus rating. The stock climbed 69% in the past year, with a 3% rise in the month leading up to September 2025, and the stock price as of October 27, 2025, was $5.12.

Protara Therapeutics does not currently have commercialized products with established market demand seasonality. Its revenue generation is primarily tied to its research and development activities and potential future regulatory approvals. Stock price movements may show "seasonality," but this does not reflect seasonal demand for its products or services.

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Their lead asset, TARA-002, is in late-stage development for non-muscle invasive bladder cancer and lymphatic malformations. They are also developing intravenous choline chloride for intestinal failure-associated liver disease.

Protara Therapeutics is headquartered in New York City, New York, United States. Its operations and clinical trials are primarily within the U.S., with no indication of a broader international footprint for current activities or product sales.

Protara Therapeutics' brand reputation in the past year appears to be largely positive, driven by promising clinical developments and favorable analyst sentiment. The company has received "Strong Buy" ratings from analysts, with a consensus indicating optimism about its future. Positive interim results from the Phase 2 trial of TARA-002 for non-muscle invasive bladder cancer, demonstrating significant response durability, have contributed to this positive perception. The company's inclusion in the Russell 3000 Index also enhanced its visibility and could be seen as a positive indicator of its market standing.

Protara Therapeutics, Inc. has a diverse ownership structure. Institutional shareholders hold 77.02% of the company, while Protara Therapeutics insiders own 82.51%, and retail investors hold 0.00%. Major institutional owners include Janus Henderson Group PLC, BlackRock, Inc., and Vanguard Group Inc. Key individual owners include Hubert Birner, Abingworth LLP, and John Gordon Freund.